BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bull JJ, Nuismer SL, Antia R. Recombinant vector vaccine evolution. PLoS Comput Biol 2019;15:e1006857. [PMID: 31323032 DOI: 10.1371/journal.pcbi.1006857] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Carascal MB, Pavon RDN, Rivera WL. Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response. Front Immunol 2022;13:878943. [PMID: 35663997 DOI: 10.3389/fimmu.2022.878943] [Reference Citation Analysis]
2 Lee MH, Kim BJ. COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity. J Microbiol 2022;60:321-34. [PMID: 35157221 DOI: 10.1007/s12275-022-1621-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bukar AM, Jesse FFA, Abdullah CAC, Noordin MM, Lawan Z, Mangga HK, Balakrishnan KN, Azmi MM. Immunomodulatory Strategies for Parapoxvirus: Current Status and Future Approaches for the Development of Vaccines against Orf Virus Infection. Vaccines (Basel) 2021;9:1341. [PMID: 34835272 DOI: 10.3390/vaccines9111341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hernández-Bello J, Morales-Núñez JJ, Machado-Sulbarán AC, Díaz-Pérez SA, Torres-Hernández PC, Balcázar-Félix P, Gutiérrez-Brito JA, Lomelí-Nieto JA, Muñoz-Valle JF. Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2. Vaccines (Basel) 2021;9:1047. [PMID: 34579284 DOI: 10.3390/vaccines9091047] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
5 Verdecia M, Kokai-Kun JF, Kibbey M, Acharya S, Venema J, Atouf F. COVID-19 vaccine platforms: Delivering on a promise? Hum Vaccin Immunother 2021;17:2873-93. [PMID: 34033528 DOI: 10.1080/21645515.2021.1911204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Saygili E, Yildiz-Ozturk E, Green MJ, Ghaemmaghami AM, Yesil-Celiktas O. Human lung-on-chips: Advanced systems for respiratory virus models and assessment of immune response. Biomicrofluidics 2021;15:021501. [PMID: 33791050 DOI: 10.1063/5.0038924] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
7 Sakr MM, Elsayed NS, El-Housseiny GS. Latest updates on SARS-CoV-2 genomic characterization, drug, and vaccine development; a comprehensive bioinformatics review. Microb Pathog 2021;154:104809. [PMID: 33647446 DOI: 10.1016/j.micpath.2021.104809] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 D'Amico C, Fontana F, Cheng R, Santos HA. Development of vaccine formulations: past, present, and future. Drug Deliv Transl Res 2021;11:353-72. [PMID: 33598818 DOI: 10.1007/s13346-021-00924-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
9 Mehmood I, Ijaz M, Ahmad S, Ahmed T, Bari A, Abro A, Allemailem KS, Almatroudi A, Tahir Ul Qamar M. SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development. Int J Environ Res Public Health 2021;18:1626. [PMID: 33567746 DOI: 10.3390/ijerph18041626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
10 Antia R, Ahmed H, Bull JJ. Directed attenuation to enhance vaccine immunity. PLoS Comput Biol 2021;17:e1008602. [PMID: 33524036 DOI: 10.1371/journal.pcbi.1008602] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Yang D. Application of Nanotechnology in the COVID-19 Pandemic. Int J Nanomedicine 2021;16:623-49. [PMID: 33531805 DOI: 10.2147/IJN.S296383] [Cited by in Crossref: 9] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
12 Layman NC, Tuschhoff BM, Nuismer SL. Designing transmissible viral vaccines for evolutionary robustness and maximum efficiency. Virus Evol 2021;7:veab002. [PMID: 33680502 DOI: 10.1093/ve/veab002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Chauhan N, Soni S, Gupta A, Aslam M, Jain U. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review. J Med Virol 2021;93:1967-82. [PMID: 33270225 DOI: 10.1002/jmv.26709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
14 Butkovich N, Li E, Ramirez A, Burkhardt AM, Wang SW. Advancements in protein nanoparticle vaccine platforms to combat infectious disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1681. [PMID: 33164326 DOI: 10.1002/wnan.1681] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
15 Layman NC, Tuschhoff BM, Basinski AJ, Remien CH, Bull JJ, Nuismer SL. Suppressing evolution in genetically engineered systems through repeated supplementation. Evol Appl 2021;14:348-59. [PMID: 33664781 DOI: 10.1111/eva.13119] [Reference Citation Analysis]
16 Todorov G, Uversky VN. A Possible Path towards Rapid Development of Live-Attenuated SARS-CoV-2 Vaccines: Plunging into the Natural Pool. Biomolecules 2020;10:E1438. [PMID: 33066343 DOI: 10.3390/biom10101438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Pandey SC, Pande V, Sati D, Upreti S, Samant M. Vaccination strategies to combat novel corona virus SARS-CoV-2. Life Sci 2020;256:117956. [PMID: 32535078 DOI: 10.1016/j.lfs.2020.117956] [Cited by in Crossref: 29] [Cited by in F6Publishing: 37] [Article Influence: 14.5] [Reference Citation Analysis]
18 Willemsen A, Zwart MP. On the stability of sequences inserted into viral genomes. Virus Evol 2019;5:vez045. [PMID: 31741748 DOI: 10.1093/ve/vez045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]